XNYS
RFL
Market cap75mUSD
Oct 08, Last price
1.48USD
1D
0.00%
1Q
-33.63%
IPO
-69.37%
Name
Rafael Holdings Inc
Chart & performance
P/E
—
P/S
82.66
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.29%
Rev. gr., 5y
-28.51%
Revenues
917k
+43.96%
Net income
-31m
L-11.30%
CFO
-19m
L+142.55%
Dividend
Dec 18, 20090.02 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Key people
Executive Chairman of the Board, President, Chief Executive Officer · since 2025
N. Scott Fine
Non-Executive Vice Chairman of the Board · since 2025
Chief Financial Officer · since 2023
Joshua Fine
Chief Operating Officer · since 2025
Stephen Greenberg
Lead Independent Director · since 2018
Lead Independent Director · since 2025
Susan Bernstein
Director · since 2024
Mark Stein
Independent Director · since 2024
Michael Weiss
Independent Director · since 2018
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑07 | 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||